Pricing Log in Create free account
Saturday 17 October 2026 Export EW’s income statement to Excel — free account

Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

86.60 1.50 −1.70%
Market cap
$50.8B
P/E
49.8×
Fwd P/E
30.7×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Edwards Lifesciences Corporation 10-Q filed Aug 4, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:14 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 6, 2026: 8 added · 27 modified; 11 with only figures updated

  1. Modified · Overview

    In February 2026, we acquired Autus Valve Technologies, Inc. (“Autus”) for total consideration of $128.9 million with contingent consideration of up to $132.5 million payable based on the achievement of certain regulatory and sales milestones. The results of Autus have been included in our condensed consolidated financial statements from the date of the acquisition.

34 more changes in this Item, word by word, in Powerpack.

Powerpack